Anzeige
Mehr »
Login
Sonntag, 24.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 553001 | ISIN: IL0010852080 | Ticker-Symbol: CW9
Berlin
22.11.24
08:02 Uhr
1,358 Euro
+0,028
+2,11 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COMPUGEN LTD Chart 1 Jahr
5-Tage-Chart
COMPUGEN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,3181,38022.11.

Aktuelle News zur COMPUGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
COMPUGEN Aktie jetzt für 0€ handeln
12.11.Compugen Ltd reports results for the quarter ended September 30 - Earnings Summary3
12.11.Compugen: EPS übertrifft Schätzungen um 0,11 $ - Umsatz besser als erwartet3
12.11.Compugen earnings beat by $0.11, revenue topped estimates2
12.11.Compugen GAAP EPS of $0.01 misses by $0.05, revenue of $17.13M misses by $0.54M4
12.11.Compugen Ltd.: Compugen Reports Third Quarter 2024 Results86Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors...
► Artikel lesen
05.11.COMPUGEN LTD - 6-K, Report of foreign issuer-
24.10.Compugen Gears Up to Report Q3 Earnings: Here's What to Expect5
13.09.COMPUGEN LTD - 6-K, Report of foreign issuer4
06.08.Compugen earnings beat by $0.07, revenue topped estimates6
06.08.Compugen: EPS übertrifft Schätzungen um 0,07 $ - Umsatz besser als erwartet2
06.08.Compugen Ltd.: Compugen Reports Second Quarter 2024 Results122FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study...
► Artikel lesen
05.08.Compugen Q2 2024 Earnings Preview2
05.08.COMPUGEN LTD - 6-K, Report of foreign issuer4
29.07.Compugen Ltd.: Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors185FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer...
► Artikel lesen
29.07.COMPUGEN LTD - 6-K, Report of foreign issuer1
30.05.COMPUGEN LTD - 6-K, Report of foreign issuer2
30.05.Compugen Ltd.: Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig597Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening...
► Artikel lesen
20.05.Compugen Ltd.: Compugen Reports First Quarter 2024 Results190Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsatellite...
► Artikel lesen
15.05.Compugen Ltd.: Compugen Appoints David Silberman as Chief Financial Officer174HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...
► Artikel lesen
05.03.Compugen Ltd.: Compugen Reports Fourth Quarter and Full Year 2023 Results253Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1